SlideShare a Scribd company logo
1 of 26
The Cancer Medication Geographical
Roulette in Canada
November 26, 2015
Webinar Overview
• Introductions
• Welcome to Guest Presenter
– Susan Turner, Turner and Associates
• Review of Canadian Cancer Care
• Cancer Treatment Coverage Map
• The Cdn Cancer Meds Funding Review and
Approval Process
• The Impact on Patients
• Questions from Audience
• Conclusion
2
Welcome Susan Turner
She has worked with the Canadian Cancer Society, the Canadian
Cancer Action Network and the Campaign to Control Cancer,
preparing reports and conferences and facilitating working
groups to take action to improve cancer medications access.
3
Susan Turner, President of Turner &
Associates Inc., is an independent
consultant who has been involved
in the area of cancer medications
access for 10 years.
Review of Canadian Cancer Care
• Four models in Canada
– Comprehensive care provided via a provincial
cancer agency (BC, AB, SK)
– Care co-ordinated by a provincial cancer agency,
with shared responsibility for treatment coverage
(MB, ON)
– Centralized institutional/regional care with shared
responsibility for treatment coverage (NF, PE)
– Hospital-based care with shared responsibility for
treatment coverage (QC, NB, NS)
4
Source: Derived from data presented in Turner and Associates,
Issues of Access to Cancer Drugs in Canada, April 2008, p. 15
Public Funding for Cancer Treatment Meds Funding Review Process
Cancer Agency Individual Hospitals /
Regions
Public Drug Plan Cancer Agency Individual Hospitals /
Regions
Public Drug Plan
Cancer Treatment Coverage Map
6
CanadianPharmaceuticalReviewand Approval Process
Drug Development
Health Canada Review
Patented Medicine
Prices Review Board
Health Technology
Assessment
Provincial Drug Plans
Patient Access
Hospitals
Private Drug
Plans
pCPA
7
Manufacturer submits
Health Canada issues NOC and DIN
Manufacturer submits
pCODR products CDR products Non pCODR, Non CDR
PCPA
No Negotiations, collective or
individual
Pan Canadian Negotiations Dealt with at the P/T levels
Confirm participation and lead jurisdiction
PCPA informs manufacturer of decision
PLA with individual jurisdictions
No
Yes decisions and No decisions
Yes
Province specific review where applicable
PCPAPROCESS
pCPA Process Map
LOI signed
7
What are the impacts on
patients
…. and what can you do
about it?
8
How well is Canada doing?
9
1.Canada’s utilization of cancer
medicines ranked 13 among 14
developed countries in 2010
2. Canada ranked 21st of the 32
countries in the Organization for
Economic Development and
Cooperation (OECD) for access
to cancer medicines in 2011-12
1. Professor Sir Mike Richards. Extent and causes of international variations in drug usage. A report for the Secretary of State for Health. July 2010.
2. Wyatt Health Management. The Rx&D International Report on Access to Medicines 2011-12.
10
Impact #1: Not all cancer medicines
are approved in Canada
• More than 50 new cancer medicines and
indications are available outside Canada
11
CanadianPharmaceuticalReviewand Approval Process
Drug Development
Health Canada Review
Patented Medicine
Prices Review Board
Health Technology
Assessment
Provincial Drug Plans
Patient Access
Hospitals
Private Drug
Plans
pCPA
Why are some cancer medicines not
available in Canada?
1. Medication is still in clinical trials
2. Manufacturer has not submitted for approval
(or submitted later)
3. Health Canada review process is slower
12
Regulatory approvals
• Median delay in approval = 9 months
• Health Canada delay is 3 months
• Delays due to manufacturers unknown
13
14
Action: Advocacy for regulatory reform
Impact #2: Coverage is essential
• The average cost of newer cancer medicines taken at
home is $72,300 (per course of treatment or per
year)
• Many Canadian oncologists do not recommend a
cancer medication if the patient is not covered
15
16
CanadianPharmaceuticalReviewand Approval Process
Drug Development
Health Canada Review
Patented Medicine
Prices Review Board
Health Technology
Assessment
Provincial Drug Plans
Patient Access
Hospitals
Private Drug
Plans
pCPA
Where are the biggest holes in our
patchwork quilt of coverage?
17
18
Issue: Unequal coverage of take-home &
hospital-administered cancer medicines
19
cancertaintyforall.ca
Action: CanCertainty
20
Issue: Provinces slow to approve
new medications
Speed of public drug plan decisions
21
BC AB SK MB ON QC NB PE NS NL YT NIHB
Funded 53 52 56 54 59 46 42 21 46 41 24 4
Rejected 12 10 10 8 5 9 9 21 10 15 10 11
Under review/pCPA 10 10 6 12 9 17 21 32 18 16 8 27
Funding Status of New Cancer Drugs & Indications Marketed Since 2006 (as of Aug 2015)
22
Action: Advocacy for standards for
provincial decision timelines
23
Issue: Strict authorization criteria
24
Action: Advocacy for independent
appeals processes
Q&A
25
Canadian Cancer Survivor Network
Contact Info
Canadian Cancer Survivor Network
1750 Courtwood Crescent, Suite 210
Ottawa, ON K2C 2B5
Telephone / Téléphone : 613-898-1871
E-mail jmanthorne@survivornet.ca or mforrest@survivornet.ca
Web site www.survivornet.ca
Blog: http://jackiemanthornescancerblog.blogspot.com/
Twitter: @survivornetca
Facebook: www.facebook.com/CanadianSurvivorNet
Pinterest: http://pinterest.com/survivornetwork/
26

More Related Content

What's hot

Canada Market Access Briefing
Canada Market Access BriefingCanada Market Access Briefing
Canada Market Access BriefingMichael Jacobson
 
Private Insurance Plans - Do they have a future in Canada?
Private Insurance Plans - Do they have a future in Canada?Private Insurance Plans - Do they have a future in Canada?
Private Insurance Plans - Do they have a future in Canada?Canadian Cancer Survivor Network
 
Webinar: Healthcare in the Federal Budget and How It May Affect Patients
Webinar: Healthcare in the Federal Budget and How It May Affect Patients Webinar: Healthcare in the Federal Budget and How It May Affect Patients
Webinar: Healthcare in the Federal Budget and How It May Affect Patients Canadian Cancer Survivor Network
 
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canadian Organization for Rare Disorders
 
Pan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar Slides
Pan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar SlidesPan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar Slides
Pan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar SlidesCanadian Organization for Rare Disorders
 
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)Canadian Organization for Rare Disorders
 
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...Canadian Organization for Rare Disorders
 
Patient Input: What is asked for and what is helpful in a patient submission
Patient Input: What is asked for and what is helpful in a patient submissionPatient Input: What is asked for and what is helpful in a patient submission
Patient Input: What is asked for and what is helpful in a patient submissionCanadian Organization for Rare Disorders
 

What's hot (20)

The IBM report on the pCPA
The IBM report on the pCPAThe IBM report on the pCPA
The IBM report on the pCPA
 
Canada Market Access Briefing
Canada Market Access BriefingCanada Market Access Briefing
Canada Market Access Briefing
 
Access to Drugs for Rare Diseases in Canada - April 2014
Access to Drugs for Rare Diseases in Canada - April 2014Access to Drugs for Rare Diseases in Canada - April 2014
Access to Drugs for Rare Diseases in Canada - April 2014
 
Private Insurance Plans - Do they have a future in Canada?
Private Insurance Plans - Do they have a future in Canada?Private Insurance Plans - Do they have a future in Canada?
Private Insurance Plans - Do they have a future in Canada?
 
Understanding your health insurance at work
Understanding your health insurance at workUnderstanding your health insurance at work
Understanding your health insurance at work
 
Webinar: Healthcare in the Federal Budget and How It May Affect Patients
Webinar: Healthcare in the Federal Budget and How It May Affect Patients Webinar: Healthcare in the Federal Budget and How It May Affect Patients
Webinar: Healthcare in the Federal Budget and How It May Affect Patients
 
Rare Disorders Policies in Canada: Who’s who and what’s what
Rare Disorders Policies in Canada: Who’s who and what’s whatRare Disorders Policies in Canada: Who’s who and what’s what
Rare Disorders Policies in Canada: Who’s who and what’s what
 
Rare Disease access issues 2015 v2
Rare Disease access issues 2015 v2Rare Disease access issues 2015 v2
Rare Disease access issues 2015 v2
 
RDD 2020 Day 1 PM: Health Canada Regulatory Update
RDD 2020 Day 1 PM: Health Canada Regulatory UpdateRDD 2020 Day 1 PM: Health Canada Regulatory Update
RDD 2020 Day 1 PM: Health Canada Regulatory Update
 
Examining Models for a National Pharmacare Program
Examining Models for a National Pharmacare ProgramExamining Models for a National Pharmacare Program
Examining Models for a National Pharmacare Program
 
Case study cdr p cpa re kuvan for cord november 2015
Case study cdr p cpa re kuvan for cord november 2015Case study cdr p cpa re kuvan for cord november 2015
Case study cdr p cpa re kuvan for cord november 2015
 
Maureen smith patient submissionspresentation.m smith.nov2015
Maureen smith patient submissionspresentation.m smith.nov2015Maureen smith patient submissionspresentation.m smith.nov2015
Maureen smith patient submissionspresentation.m smith.nov2015
 
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
 
Drug Access Navigation - An Insider's Perspective
Drug Access Navigation - An Insider's PerspectiveDrug Access Navigation - An Insider's Perspective
Drug Access Navigation - An Insider's Perspective
 
Pan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar Slides
Pan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar SlidesPan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar Slides
Pan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar Slides
 
Barbara Sabourin regulating drugs in canada v2
Barbara Sabourin regulating drugs in canada v2Barbara Sabourin regulating drugs in canada v2
Barbara Sabourin regulating drugs in canada v2
 
RWD/RWE for Rare Disease Drugs Webinar
RWD/RWE for Rare Disease Drugs WebinarRWD/RWE for Rare Disease Drugs Webinar
RWD/RWE for Rare Disease Drugs Webinar
 
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
 
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
 
Patient Input: What is asked for and what is helpful in a patient submission
Patient Input: What is asked for and what is helpful in a patient submissionPatient Input: What is asked for and what is helpful in a patient submission
Patient Input: What is asked for and what is helpful in a patient submission
 

Similar to The Cancer Medication Geographical Roulette in Canada

Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...Dr. Tayaba Khan
 
Cadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinal
Cadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinalCadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinal
Cadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinalCADTH Symposium
 
Summer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal Election
Summer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal ElectionSummer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal Election
Summer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal ElectionCanadian Organization for Rare Disorders
 
CCSN Advocacy Webinar #2
CCSN Advocacy Webinar #2CCSN Advocacy Webinar #2
CCSN Advocacy Webinar #2Tiffany Glover
 
Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...
Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...
Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...Canadian Organization for Rare Disorders
 
CanREValue: A Framework for the Incorporation of Real-World Evidence (RWE) in...
CanREValue: A Framework for the Incorporation of Real-World Evidence (RWE) in...CanREValue: A Framework for the Incorporation of Real-World Evidence (RWE) in...
CanREValue: A Framework for the Incorporation of Real-World Evidence (RWE) in...Canadian Cancer Survivor Network
 
Does Canada need an Orphan Drug Policy to incentivize drug development and su...
Does Canada need an Orphan Drug Policy to incentivize drug development and su...Does Canada need an Orphan Drug Policy to incentivize drug development and su...
Does Canada need an Orphan Drug Policy to incentivize drug development and su...Canadian Organization for Rare Disorders
 
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...Arvind Mani
 
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...Canadian Organization for Rare Disorders
 
Update on Cancer Meds Review and Approval 23Mar2023.pptx
Update on Cancer Meds Review and Approval 23Mar2023.pptxUpdate on Cancer Meds Review and Approval 23Mar2023.pptx
Update on Cancer Meds Review and Approval 23Mar2023.pptxCCSNCommunication
 
Oct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
Oct 25   CAPHC Breakfast Symposium - Sponsored by Alexion - CORDOct 25   CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
Oct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORDGlenna Gosewich
 
What is patient engagement at CADTH, and how can you get involved?
What is patient engagement at CADTH, and how can you get involved?What is patient engagement at CADTH, and how can you get involved?
What is patient engagement at CADTH, and how can you get involved?Canadian Cancer Survivor Network
 

Similar to The Cancer Medication Geographical Roulette in Canada (20)

CBoC_IMC_Time to Patient Presentation_CCSN.pdf
CBoC_IMC_Time to Patient Presentation_CCSN.pdfCBoC_IMC_Time to Patient Presentation_CCSN.pdf
CBoC_IMC_Time to Patient Presentation_CCSN.pdf
 
RDD 2020 Day 1 AM - Durhane Wong-Rieger
RDD 2020 Day 1 AM - Durhane Wong-RiegerRDD 2020 Day 1 AM - Durhane Wong-Rieger
RDD 2020 Day 1 AM - Durhane Wong-Rieger
 
Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...
 
Cadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinal
Cadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinalCadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinal
Cadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinal
 
Summer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal Election
Summer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal ElectionSummer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal Election
Summer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal Election
 
CCSN Advocacy Webinar #2
CCSN Advocacy Webinar #2CCSN Advocacy Webinar #2
CCSN Advocacy Webinar #2
 
Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...
Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...
Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...
 
Webinar: Investing $1.5b in A Sustainable Rare Disease Ecosystem
Webinar: Investing $1.5b in A Sustainable Rare Disease EcosystemWebinar: Investing $1.5b in A Sustainable Rare Disease Ecosystem
Webinar: Investing $1.5b in A Sustainable Rare Disease Ecosystem
 
CanREValue: A Framework for the Incorporation of Real-World Evidence (RWE) in...
CanREValue: A Framework for the Incorporation of Real-World Evidence (RWE) in...CanREValue: A Framework for the Incorporation of Real-World Evidence (RWE) in...
CanREValue: A Framework for the Incorporation of Real-World Evidence (RWE) in...
 
Does Canada need an Orphan Drug Policy to incentivize drug development and su...
Does Canada need an Orphan Drug Policy to incentivize drug development and su...Does Canada need an Orphan Drug Policy to incentivize drug development and su...
Does Canada need an Orphan Drug Policy to incentivize drug development and su...
 
Durhane Wong-Rieger (CORD) Canada's Rare Disease Strategy Brief Overview
Durhane Wong-Rieger (CORD) Canada's Rare Disease Strategy Brief Overview Durhane Wong-Rieger (CORD) Canada's Rare Disease Strategy Brief Overview
Durhane Wong-Rieger (CORD) Canada's Rare Disease Strategy Brief Overview
 
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...
 
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...
 
Update on Cancer Meds Review and Approval 23Mar2023.pptx
Update on Cancer Meds Review and Approval 23Mar2023.pptxUpdate on Cancer Meds Review and Approval 23Mar2023.pptx
Update on Cancer Meds Review and Approval 23Mar2023.pptx
 
Update on Cancer Meds Review and Approval 23Mar2023.pptx
Update on Cancer Meds Review and Approval 23Mar2023.pptxUpdate on Cancer Meds Review and Approval 23Mar2023.pptx
Update on Cancer Meds Review and Approval 23Mar2023.pptx
 
When pCODR Says "No", Then What?
When pCODR Says "No", Then What?When pCODR Says "No", Then What?
When pCODR Says "No", Then What?
 
Oct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
Oct 25   CAPHC Breakfast Symposium - Sponsored by Alexion - CORDOct 25   CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
Oct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
 
Oct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
Oct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORDOct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
Oct 25 CAPHC Breakfast Symposium - Sponsored by Alexion - CORD
 
What is patient engagement at CADTH, and how can you get involved?
What is patient engagement at CADTH, and how can you get involved?What is patient engagement at CADTH, and how can you get involved?
What is patient engagement at CADTH, and how can you get involved?
 
Drug Approval & Reimbursement Processes
Drug Approval & Reimbursement ProcessesDrug Approval & Reimbursement Processes
Drug Approval & Reimbursement Processes
 

More from Canadian Cancer Survivor Network

Challenges and Potential Solutions for Improving Health Technology Assessment...
Challenges and Potential Solutions for Improving Health Technology Assessment...Challenges and Potential Solutions for Improving Health Technology Assessment...
Challenges and Potential Solutions for Improving Health Technology Assessment...Canadian Cancer Survivor Network
 
CCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptx
CCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptxCCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptx
CCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptxCanadian Cancer Survivor Network
 
CCSN Presentation Getting Your Gut What It Needs A Post Cancer Treatment Guid...
CCSN Presentation Getting Your Gut What It Needs A Post Cancer Treatment Guid...CCSN Presentation Getting Your Gut What It Needs A Post Cancer Treatment Guid...
CCSN Presentation Getting Your Gut What It Needs A Post Cancer Treatment Guid...Canadian Cancer Survivor Network
 
Young Adult Cancer Canada & the 8 Things You Need to Know About Cancer in the...
Young Adult Cancer Canada & the 8 Things You Need to Know About Cancer in the...Young Adult Cancer Canada & the 8 Things You Need to Know About Cancer in the...
Young Adult Cancer Canada & the 8 Things You Need to Know About Cancer in the...Canadian Cancer Survivor Network
 

More from Canadian Cancer Survivor Network (20)

Challenges and Potential Solutions for Improving Health Technology Assessment...
Challenges and Potential Solutions for Improving Health Technology Assessment...Challenges and Potential Solutions for Improving Health Technology Assessment...
Challenges and Potential Solutions for Improving Health Technology Assessment...
 
Pancreatic Cancer an Overview - CCSN 2024-02-29
Pancreatic Cancer an Overview - CCSN 2024-02-29Pancreatic Cancer an Overview - CCSN 2024-02-29
Pancreatic Cancer an Overview - CCSN 2024-02-29
 
Bulk Importation MSSC Presentation 2024-02-final .pdf
Bulk Importation MSSC Presentation 2024-02-final .pdfBulk Importation MSSC Presentation 2024-02-final .pdf
Bulk Importation MSSC Presentation 2024-02-final .pdf
 
CCSN Presentation John Adams February 1 2024 2.pptx
CCSN Presentation John Adams February 1 2024 2.pptxCCSN Presentation John Adams February 1 2024 2.pptx
CCSN Presentation John Adams February 1 2024 2.pptx
 
CCSN Webinar 2023 2023 11 Diet for PEP.pdf
CCSN Webinar 2023 2023 11 Diet for PEP.pdfCCSN Webinar 2023 2023 11 Diet for PEP.pdf
CCSN Webinar 2023 2023 11 Diet for PEP.pdf
 
CCSN Webinar - EAOCRC FINAL [Autosaved].pptx
CCSN Webinar - EAOCRC FINAL [Autosaved].pptxCCSN Webinar - EAOCRC FINAL [Autosaved].pptx
CCSN Webinar - EAOCRC FINAL [Autosaved].pptx
 
CCSN David Ma Nov 9 2023 final.pptx
CCSN David Ma Nov 9 2023 final.pptxCCSN David Ma Nov 9 2023 final.pptx
CCSN David Ma Nov 9 2023 final.pptx
 
CCSN_Husereau_2_Nov.pdf
CCSN_Husereau_2_Nov.pdfCCSN_Husereau_2_Nov.pdf
CCSN_Husereau_2_Nov.pdf
 
CCSN Breast Screening for Women in the 40s(1).pptx
CCSN Breast Screening for Women in the 40s(1).pptxCCSN Breast Screening for Women in the 40s(1).pptx
CCSN Breast Screening for Women in the 40s(1).pptx
 
CCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptx
CCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptxCCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptx
CCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptx
 
AsbestosPresentation-PCNforCCSN-Final-Sept28.pdf
AsbestosPresentation-PCNforCCSN-Final-Sept28.pdfAsbestosPresentation-PCNforCCSN-Final-Sept28.pdf
AsbestosPresentation-PCNforCCSN-Final-Sept28.pdf
 
CCSN EUPROMS.pptx
CCSN EUPROMS.pptxCCSN EUPROMS.pptx
CCSN EUPROMS.pptx
 
survivornettalkCancerandWorkP.pdf
survivornettalkCancerandWorkP.pdfsurvivornettalkCancerandWorkP.pdf
survivornettalkCancerandWorkP.pdf
 
Returning-to-Work-after-Cancer-Treatment_BB.pptx
Returning-to-Work-after-Cancer-Treatment_BB.pptxReturning-to-Work-after-Cancer-Treatment_BB.pptx
Returning-to-Work-after-Cancer-Treatment_BB.pptx
 
CCSN Long Covid FINAL.pptx
CCSN Long Covid FINAL.pptxCCSN Long Covid FINAL.pptx
CCSN Long Covid FINAL.pptx
 
CCSN Presentation Getting Your Gut What It Needs A Post Cancer Treatment Guid...
CCSN Presentation Getting Your Gut What It Needs A Post Cancer Treatment Guid...CCSN Presentation Getting Your Gut What It Needs A Post Cancer Treatment Guid...
CCSN Presentation Getting Your Gut What It Needs A Post Cancer Treatment Guid...
 
CCSN Powerpoint Template_planningfornewreality.pptx
CCSN Powerpoint Template_planningfornewreality.pptxCCSN Powerpoint Template_planningfornewreality.pptx
CCSN Powerpoint Template_planningfornewreality.pptx
 
SayaniAmbreen_SocialInequalitiesANDCancer_April2023.pdf
SayaniAmbreen_SocialInequalitiesANDCancer_April2023.pdfSayaniAmbreen_SocialInequalitiesANDCancer_April2023.pdf
SayaniAmbreen_SocialInequalitiesANDCancer_April2023.pdf
 
CS2FS What to expect from Advisors.pptx
CS2FS What to expect from Advisors.pptxCS2FS What to expect from Advisors.pptx
CS2FS What to expect from Advisors.pptx
 
Young Adult Cancer Canada & the 8 Things You Need to Know About Cancer in the...
Young Adult Cancer Canada & the 8 Things You Need to Know About Cancer in the...Young Adult Cancer Canada & the 8 Things You Need to Know About Cancer in the...
Young Adult Cancer Canada & the 8 Things You Need to Know About Cancer in the...
 

Recently uploaded

Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxpdamico1
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMADivya Kanojiya
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfSasikiranMarri
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATROKanhu Charan
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityHarshChauhan475104
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfSGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfHongBiThi1
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledgeassessoriafabianodea
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseSreenivasa Reddy Thalla
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Classmanuelazg2001
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxDr. Dheeraj Kumar
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 

Recently uploaded (20)

Epilepsy
EpilepsyEpilepsy
Epilepsy
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfSGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies Disease
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Class
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptx
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 

The Cancer Medication Geographical Roulette in Canada

  • 1. The Cancer Medication Geographical Roulette in Canada November 26, 2015
  • 2. Webinar Overview • Introductions • Welcome to Guest Presenter – Susan Turner, Turner and Associates • Review of Canadian Cancer Care • Cancer Treatment Coverage Map • The Cdn Cancer Meds Funding Review and Approval Process • The Impact on Patients • Questions from Audience • Conclusion 2
  • 3. Welcome Susan Turner She has worked with the Canadian Cancer Society, the Canadian Cancer Action Network and the Campaign to Control Cancer, preparing reports and conferences and facilitating working groups to take action to improve cancer medications access. 3 Susan Turner, President of Turner & Associates Inc., is an independent consultant who has been involved in the area of cancer medications access for 10 years.
  • 4. Review of Canadian Cancer Care • Four models in Canada – Comprehensive care provided via a provincial cancer agency (BC, AB, SK) – Care co-ordinated by a provincial cancer agency, with shared responsibility for treatment coverage (MB, ON) – Centralized institutional/regional care with shared responsibility for treatment coverage (NF, PE) – Hospital-based care with shared responsibility for treatment coverage (QC, NB, NS) 4
  • 5. Source: Derived from data presented in Turner and Associates, Issues of Access to Cancer Drugs in Canada, April 2008, p. 15 Public Funding for Cancer Treatment Meds Funding Review Process Cancer Agency Individual Hospitals / Regions Public Drug Plan Cancer Agency Individual Hospitals / Regions Public Drug Plan Cancer Treatment Coverage Map
  • 6. 6 CanadianPharmaceuticalReviewand Approval Process Drug Development Health Canada Review Patented Medicine Prices Review Board Health Technology Assessment Provincial Drug Plans Patient Access Hospitals Private Drug Plans pCPA
  • 7. 7 Manufacturer submits Health Canada issues NOC and DIN Manufacturer submits pCODR products CDR products Non pCODR, Non CDR PCPA No Negotiations, collective or individual Pan Canadian Negotiations Dealt with at the P/T levels Confirm participation and lead jurisdiction PCPA informs manufacturer of decision PLA with individual jurisdictions No Yes decisions and No decisions Yes Province specific review where applicable PCPAPROCESS pCPA Process Map LOI signed 7
  • 8. What are the impacts on patients …. and what can you do about it? 8
  • 9. How well is Canada doing? 9 1.Canada’s utilization of cancer medicines ranked 13 among 14 developed countries in 2010 2. Canada ranked 21st of the 32 countries in the Organization for Economic Development and Cooperation (OECD) for access to cancer medicines in 2011-12 1. Professor Sir Mike Richards. Extent and causes of international variations in drug usage. A report for the Secretary of State for Health. July 2010. 2. Wyatt Health Management. The Rx&D International Report on Access to Medicines 2011-12.
  • 10. 10 Impact #1: Not all cancer medicines are approved in Canada • More than 50 new cancer medicines and indications are available outside Canada
  • 11. 11 CanadianPharmaceuticalReviewand Approval Process Drug Development Health Canada Review Patented Medicine Prices Review Board Health Technology Assessment Provincial Drug Plans Patient Access Hospitals Private Drug Plans pCPA
  • 12. Why are some cancer medicines not available in Canada? 1. Medication is still in clinical trials 2. Manufacturer has not submitted for approval (or submitted later) 3. Health Canada review process is slower 12
  • 13. Regulatory approvals • Median delay in approval = 9 months • Health Canada delay is 3 months • Delays due to manufacturers unknown 13
  • 14. 14 Action: Advocacy for regulatory reform
  • 15. Impact #2: Coverage is essential • The average cost of newer cancer medicines taken at home is $72,300 (per course of treatment or per year) • Many Canadian oncologists do not recommend a cancer medication if the patient is not covered 15
  • 16. 16 CanadianPharmaceuticalReviewand Approval Process Drug Development Health Canada Review Patented Medicine Prices Review Board Health Technology Assessment Provincial Drug Plans Patient Access Hospitals Private Drug Plans pCPA
  • 17. Where are the biggest holes in our patchwork quilt of coverage? 17
  • 18. 18 Issue: Unequal coverage of take-home & hospital-administered cancer medicines
  • 20. 20 Issue: Provinces slow to approve new medications
  • 21. Speed of public drug plan decisions 21 BC AB SK MB ON QC NB PE NS NL YT NIHB Funded 53 52 56 54 59 46 42 21 46 41 24 4 Rejected 12 10 10 8 5 9 9 21 10 15 10 11 Under review/pCPA 10 10 6 12 9 17 21 32 18 16 8 27 Funding Status of New Cancer Drugs & Indications Marketed Since 2006 (as of Aug 2015)
  • 22. 22 Action: Advocacy for standards for provincial decision timelines
  • 24. 24 Action: Advocacy for independent appeals processes
  • 26. Canadian Cancer Survivor Network Contact Info Canadian Cancer Survivor Network 1750 Courtwood Crescent, Suite 210 Ottawa, ON K2C 2B5 Telephone / Téléphone : 613-898-1871 E-mail jmanthorne@survivornet.ca or mforrest@survivornet.ca Web site www.survivornet.ca Blog: http://jackiemanthornescancerblog.blogspot.com/ Twitter: @survivornetca Facebook: www.facebook.com/CanadianSurvivorNet Pinterest: http://pinterest.com/survivornetwork/ 26